Literature DB >> 9311061

Ethical issues in the management of chronic nonmalignant pain.

M Pappagallo1, L J Heinberg.   

Abstract

Chronic pain represents a challenge to patients, families, employers, and the physicians who care for these individuals. Opioids remain the mainstay of the analgesic medications for the treatment of both acute and chronic pain. Controlled release preparations of morphine, oxycodone, fentanyl and long acting opioid agents such as methadone and levorphanol have been medically and ethically accepted in managing chronic cancer pain. However, the continued use of these medications for patients with chronic noncancer pain has been fiercely debated. This article attempts to reconcile the medical and ethical dilemma of using opioid medications for chronic noncancer pain. Growing clinical experience in the field of pain medicine has helped to clarify: (1) the misunderstanding of addiction, physical dependence and analgesic tolerance, (2) the misconception that chronic opioid therapy inevitably causes personality changes, depression, and impairment of cognitive and physical function, (3) the lack of information on the correct use of opioid analgesics with regard to titration and management of related side effects. The behavioral management of pain patients undergoing chronic opioid therapy is also discussed. A protocol for optimal patient management is proposed. Particular emphasis is given to the consent form, behavioral contracting, and the consequences of noncompliance. The importance of psychologic evaluation before a long-term opioid trial, to minimize future complications, is stressed. Although most patients on the opioid regimen do well, special attention must be given to patients with current addiction, a past history of addiction, or current misuse of opioid medications. Pharmacologic and conservative interventions are often warranted in those patients with significant behavioral problems. If such strategies fail, and chronic opioid therapy is deemed necessary, some treatment guidelines are offered.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9311061     DOI: 10.1055/s-2008-1040930

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  5 in total

1.  Health outcomes and costs in patients with osteoarthritis and chronic pain treated with opioids in Spain: the OPIOIDS real-world study.

Authors:  Antoni Sicras-Mainar; Carlos Tornero-Tornero; Francisco Vargas-Negrín; Isabel Lizarraga; Javier Rejas-Gutierrez
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-09-17       Impact factor: 5.346

Review 2.  The use of opioids in the treatment of osteoarthritis: when, why, and how?

Authors:  Jeremy L R Goodwin; Jan J Kraemer; Zahid H Bajwa
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

3.  In vivo activation of a mutant mu-opioid receptor by antagonist: future direction for opiate pain treatment paradigm that lacks undesirable side effects.

Authors:  Wanling Yang; Ping-Yee Law; Xiaohong Guo; Horace H Loh
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-13       Impact factor: 11.205

4.  Patient versus therapist alliance: whose perception matters?

Authors:  Angela R Bethea; Michelle C Acosta; Deborah L Haller
Journal:  J Subst Abuse Treat       Date:  2007-12-20

Review 5.  The use of opioids in the treatment of osteoarthritis: when, why, and how?

Authors:  Jeremy L R Goodwin; Jan J Kraemer; Zahid H Bajwa
Journal:  Curr Pain Headache Rep       Date:  2005-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.